influenza

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses nationwide.  The Details: The Louisiana Department of Health said the patient, who was over the age...

The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and...

Moderna Inc (NASDAQ: MRNA) says that it's on its way to having two mRNA vaccines against different seasonal flu viruses. The Company released the first early data from Phase 1 study of mRNA-1010, announcing that all doses of the shot significantly boosted antibodies in younger...

SAB Biotherapeutics Inc (NASDAQ: SABS) has announced data from a Phase 2a challenge study of SAB-176, its investigational therapy for treating seasonal influenza. SAB-176 is a quadrivalent fully human polyclonal antibody therapeutic candidate designed to treat moderate to severe Type A and B...

The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Rapivab (peramivir injection) The govt will pay approximately $7 million for the Antiviral influenza...

Privately held company Polyrizon Ltd, in which Medigus Ltd (NASDAQ: MDGS) owns 35.86% of share capital, has announced preclinical data for its Capture and Contain (C&C) platform technology. Related Content: Medigus-Backed Polyrizon's COVID-19 Technology...

Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The 280-subject trial will assess the safety and immunogenicity (...

Novavax, Inc. (NVAX) announced positive results from the animal study of its combo vaccine for influenza and COVID-19. The positive news however did little to stem the sell-off in shares that began in late April. What Happened: Gaithersburg, Maryland-based Novavax said data from a...

Cidara Therapeutics Inc (NASDAQ: CDTX) has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize Cidara's Cloudbreak antiviral...

At a time when the flu season is typically coming to a close, the Centers for Disease Control and Prevention said this week that the number of cases and related medical visits continue to be elevated. Flu season typically ranges from November to March, with flu-like illness peaking in February...

Altimmune Inc (NASDAQ: ALT), which develops immunotherapies and vaccines, is seeing its stock surge on 15 times its average volume after the company reported the results of a midstage study of its lead candidate NasoVAX. What Happened The nanocap biotech company said Tuesday that additional data...

Altimmune Inc (NASDAQ: ALT) shares have been on a roller coaster ride since mid-September, swinging in a wild range of $26.23 to $4.27.  The shares were jumping 28.87 percent to $9.33 in premarket trading Monday before falling more than 30 percent to $5.06 after the open.  What Happened...

Diagnostic healthcare products manufacturer Quidel Corporation (NASDAQ: QDEL)'s shares are not fully reflecting the company's growth potential and likely positive estimate revision bias, according to Raymond James.  The Analyst Raymond James analyst Nicholas Jansen upgraded shares...

The lethal H3N2 flu strain and comorbid diseases claimed at least 4,000 lives in the U.S. last week, according to the Centers for Disease Control. The illness rate now rivals that of the swine flu in 2009 and exceeds that of the last severe flu season in 2003, when a new strain emerged. “Flu...